Evaluation Efficacy and Safety of Vortioxetine 20 mg/d versus Placebo for Treatment Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journals Menu

Follow SCIRP

ISSN Print: 2157-9423
ISSN Online: 2157-9431
www.scirp.org/journal/pp
E-mail: pp@scirp.org

"Evaluation Efficacy and Safety of Vortioxetine 20 mg/d versus Placebo for Treatment Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials"
written by Masoud Behzadifar, Hamidreza Dehghan, Korush Saki, Meysam Behzadifar, Abouzar Keshavarzi, Maryam Saran, Ali Akbari Sari,
published by Pharmacology & Pharmacy, Vol.6 No.4, 2015

has been cited by the following article(s):

[1]	Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review
	Adeliño, JM Crespo, F Mora… - Expert Opinion on …, 2022

[2]	A Comparative study of Efficacy & Safety Profile of Acetyl-L-Carnitine as Add on Therapy in the Treatment of Depression
	2021

[3]	Vortioxetine a New Generation Serotonin Reuptake Inhibitor in the Treatment of Major Depressive Disorder
	Multi-Knowledge Electronic Comprehensive Journal For Education And Science Publications, 2019

[4]	The efficacy and safety of 10 mg/day vortioxetine compared to placebo for adult major depressive disorder: a meta-analysis
	2019

[5]	The Validity of the Montgomery‐Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence
	Alcoholism: Clinical and Experimental Research, 2017

[6]	The Validity of the Montgomery–Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence
	Alcoholism: Clinical and Experimental Research, 2017

[7]	Metaanálisis de ensayos controlados con placebo y aleatorizados de vortioxetina en el tratamiento del trastorno depresivo mayor en adultos
	2016

[8]	抗抑郁新药的研究与开发
	药学进展, 2016

[9]	A Meta-Analysis of Randomized, Placebo-Controlled Trials of Vortioxetine for the Treatment of Major Depressive Disorder in Adults
	European Neuropsychopharmacology, 2016

[1]	Vortioxetine in major depressive disorder: from mechanisms of action to clinical studies. An updated review Expert Opinion on Drug Safety, 2022 DOI:10.1080/14740338.2022.2019705

[2]	The Validity of the Montgomery-Asberg Depression Rating Scale in an Inpatient Sample with Alcohol Dependence Alcoholism: Clinical and Experimental Research, 2017 DOI:10.1111/acer.13400

[3]	A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults European Neuropsychopharmacology, 2016 DOI:10.1016/j.euroneuro.2016.03.007

Follow SCIRP